Peptide-Based Strategies: Combating Alzheimer's Amyloid β Aggregation through Ergonomic Design and Fibril Disruption.

Area of Science:

• Biochemistry
• Neuroscience
• Drug Discovery

Background:

• Amyloid-β (Aβ) amyloidosis is a key driver of Alzheimer's disease (AD) pathogenesis, causing oxidative damage and neuronal death.
• Targeting Aβ amyloid formation or disrupting existing fibrils is crucial for combating AD progression.

Purpose of the Study:

• To optimize the antiamyloid efficiency of a previously developed peptide, NF11.
• To evaluate the potential of a modified peptide, P1, in inhibiting and disrupting Aβ42 amyloidosis.

Main Methods:

• Systematic optimization of peptide sequences.
• In vitro studies to assess inhibition of Aβ42 amyloid formation.
• Analysis of disruption of mature Aβ42 fibrils.
• Characterization of peptide-protein interactions and mechanism of action.

Main Results:

• Peptide P1, a nontoxic and serum-stable α/β hybrid peptide, significantly inhibits Aβ42 amyloid formation.
• P1 effectively disrupts mature Aβ42 fibrils into soluble, non-toxic species.
• P1 exhibits micromolar binding affinity for both monomeric and aggregated Aβ42.
• The peptide protects against apoptosis and modulates Aβ amyloidosis.

Conclusions:

• Incorporating a β-amino acid into peptides enhances stability and introduces β-breaker properties.
• Peptide P1 demonstrates significant potential as a therapeutic agent for Alzheimer's disease by modulating Aβ aggregation and promoting clearance of toxic species.